



# References for Medical Device NRAs

Alexandre Lemgruber, PAHO/WHO

Medical Devices Webinar Series USAID – IACRC – FDA  
Utilization of Voluntary Consensus Standards and Conformity  
Assessment

3 March 2022

**PAHO**



Pan American  
Health  
Organization



World Health  
Organization  
REGIONAL OFFICE FOR THE  
Americas



# REGIONAL WORKING GROUP ON MEDICAL DEVICES REGULATION

Created in 2012, with the aim of strengthening the regulatory capacity of medical devices in the Region of the Americas - 25 NRAs

Argentina	Belize	Bolivia	Brazil	Canada
Chile	Colombia	Costa Rica	Cuba	Dominican Republic
Ecuador	El Salvador	Guatemala	Guyana	Honduras
Jamaica	Mexico	Nicaragua	Panama	Paraguay
Peru	Trinidad and Tobago	Uruguay	<b>USA</b>	Venezuela





# ACTIVITIES OF THE REGIONAL WORKING GROUP

## ❖ REGIONAL MEETINGS

- ▶ Annual face-to-face meetings
- ▶ Open sessions with the stakeholders

## ❖ VIRTUAL MEETINGS

Regional Working Group

Training

- ▶ Annual Virtual Courses in collaboration with CECMED and INVIMA
- ▶ Annual face-to-face workshops on defined priority topics

- ▶ Regional Meetings in conjunction with the IMDRF Meetings
- ▶ Participation in the IMDRF meetings
- ▶ Participation in the Working Groups
- ▶ Creation of Mirror Working Groups
- ▶ Translation of technical documents

Participation in IMDRF

Technical Groups

- ▶ Reuse and Reprocessing of Medical Devices
- ▶ National Implant Registry

- ▶ Development of Basic Indicators
- ▶ Advanced indicators draft
- ▶ Participation in the meetings of the Global Benchmarking Tool + medical devices

Medical Device Indicators

Communities of Practice

- ▶ Medical Devices Regulation
- ▶ REDMA Program



# NEXT MEETING OF THE REGIONAL WORKING GROUP

April 2022

VIRTUAL MODE



Session of the Regional Working Group  
September 6, 2019 | Bogota, Colombia



Open session with Stakeholders  
September 5, 2019 | Bogota, Colombia



# CAPACITY BUILDING IN 2021

## VIRTUAL MODULE ON TECHNOVIGILANCE IN COLOMBIA

In collaboration with  
**INVIMA**

**2021**

**Spanish**  
Edition

**125**

participants registered



**14**

beneficiary countries

Bolivia, Chile, Costa Rica, Cuba, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Paraguay, Peru, Uruguay and Venezuela

### Modules

1. Introduction to Medical Devices and international overview of Technovigilance
2. Progress, challenges and projection of the Colombian Technovigilance Program
3. Steps to implement a Technovigilance Program in Colombia
4. Strengthening Technovigilance in the Context of the COVID-19 Pandemic





# PROGRAM ON EXCHANGE OF REPORTS ON ADVERSE EVENTS OF MEDICAL DEVICES - REDMA PROGRAM

## OBJECTIVES

- Exchange reports of medical devices adverse events or incidents among National Regulatory Authorities of the Americas Region
- Promote the development of Surveillance Systems

2014

The Mirror Group was established

- Secretariat:
- CECMED
  - ANVISA
  - INVIMA



2015 → 2017

Baseline documents were prepared and approved

- Criteria and Forms
- Declaration of Conformity
- Functioning of the Secretariat
- REDMA Web System User Manual



2016

Technical Meeting for the implementation of the REDMA Program in Havana



2017

**REDMA Web System** developed by **CECMED**

### PILOT STUDY

ARG, BRA, CHI, COL, CUB, MEX, ELS, PAN, DOR, URU.



2018

Technical Meeting for the REDMA Program in Havana



2019

Integration of the **REDMA Web System** within **PRAIS**

**Full implementation** of the Program on March

**CoP REDMA Program**  
44 members

Updated versions of the program documents are located in the CoP







# REDMA PROGRAM

**11**

Associate members

BOL | ECU | HND | NIC | PRY | ELS | URY | PAN | DOR | VEN

**6**

Full members

ARG | BRA | COL | CUB | CHL | MEX

**37**

**Reports**

24 Confidential - 13 public

- 86% of the reports are confidential.
- Health institutions reported 50% of the events, manufacturers 37% and users 13%.
- Risk level of the reported equipment: 38% Low-Moderate; 29% High; 21% Moderate-High; 12% Low.
- The most reported medical specialty was cardiovascular with 21%.

# REDMA PROGRAM – REDMA WEB SYSTEM

- Secure exchange of adverse event reports of medical devices.
- Integrated into the Regional Platform on Access and Innovation for Health Technologies (PRAIS).
- Access for NRAs members of the REDMA Program.
- Access to the Web System through a unique contact designated by each NRA.

Organización Panamericana de la Salud

Organización Mundial de la Salud  
ORCINA REGIONAL PARA LAS Américas

Plataforma Regional sobre Acceso e Innovación para Tecnologías Sanitarias PRAIS

CECMED  
CENTRO PARA EL CONTROL ESTATAL DE MEDICAMENTOS, EQUIPOS Y DISPOSITIVOS MÉDICOS  
Ministerio de Salud Pública de Cuba  
Centro Colaborador de la OMS/OPS

### Programa REDMA

Introduzca sus credenciales

Correo Electrónico

Contraseña

Recordarme

Entrar

Olvidé mi Contraseña

Regístrame

El Programa REDMA fue desarrollado para intercambiar reportes de eventos o incidentes adversos de dispositivos médicos entre las Autoridades Reguladoras Nacionales (ARN) de la Región de las Américas. Este consiste en un proceso de comunicación proactiva entre sus miembros que permite la toma de decisiones con base en un sistema seguro de intercambio de información. El uso de esta plataforma web está restringido únicamente a las ARN participantes del Programa.

El Programa REDMA es una iniciativa conjunta de la Organización Panamericana de la Salud/Organización Mundial de la Salud (OPS/OMS) y del Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED) de Cuba, Centro Colaborador de la OMS/OPS en Regulación de Tecnologías Sanitarias, en el marco de las actividades del Grupo de Trabajo Regional de Regulación de Dispositivos Médicos. Si requiere información adicional, favor dirigirse a [redma@paho.org](mailto:redma@paho.org).





# COLLABORATION WITH THE INTERNATIONAL MEDICAL DEVICE REGULATORS FORUM (IMDRF)

- Regional Meetings of the Working Group in conjunction with the meetings of the IMDRF.
- Participation in face-to-face and virtual meetings of the Forum.
- Participation in IMDRF Working Groups
  - Clinical evaluation of medical devices (represented by ANMAT, Argentina)
  - Personalized medical devices (represented by ANMAT, Argentina)
  - Good regulatory practices (represented by INVIMA, Colombia)
  - **NEW WORKING GROUP** Clinical evidence for In Vitro Diagnostic Medical Devices (represented by CECMED – Cuba, Ministry of Health – Uruguay and PAHO)
- Creation of Mirror Working Groups









# COLLABORATION WITH IMDRF

## MIRROR GROUPS OF IMDRF WORKING GROUPS







# COLLABORATION WITH IMDRF



6 documents translated into Spanish






# COLLABORATION WITH IMDRF

**12** documents are already in the process of being translated

1. Principles of In Vitro Diagnostic (IVD) Medical Devices Classification
2. Requirements for Regulatory Authority Recognition of Conformity Assessment Bodies Conducting Medical Device Regulatory Reviews
3. Personalized Medical Devices - Regulatory Pathways
4. Clinical Investigation
5. Clinical Evaluation
6. Tools for Assessing the Usability of Registries in Support of Regulatory Decision-Making
7. Common Data Elements for Medical Device Identification
8. Software as a Medical Device (SaMD): Key Definitions
9. UDI Guidance. Unique Device Identification (UDI) of Medical Devices
10. Principles of International System of Registries Linked to Other Data Sources and Tools
11. Unique Device Identification system (UDI system). Application Guide
12. Post-Market Clinical Follow-Up Studies



# WHO Expert Committee on Specifications for Pharmaceutical Preparations

**Fifty-fifth report, 2021**

## Annex 10

*Good reliance practices in the regulation of medical products: high level principles and considerations*

## Annex 11

*Good regulatory practices in the regulation of medical products*

Link to the document:

<https://www.who.int/publications/i/item/55th-report-of-the-who-expert-committee-on-specifications-for-pharmaceutical-preparations>





# ANNEX 11. GOOD REGULATORY PRACTICES

## PURPOSE

- Present the **high-level principles** of Good Regulatory Practices.
- Guide Member States in **prioritizing regulatory functions** according to their resources, national objectives, public health policies, medical product policies, and the medical product environment.


## SCOPE

- **Regulatory authorities**, regardless of their resources, maturity or regulatory model;
- **Supranational**, national and subnational regulatory systems;
- Health **institutions and policymakers**, laws, regulations and guidelines;
- **Regulatory networks**;
- **Parties affected or interested** in regulatory frameworks, such as industry.


## OBJECTIVES

- Ensure **robust and effective regulation** of medical products,
- Improve **quality, decision-making and regulatory compliance**,
- More **efficient regulatory systems and better public health outcomes**,
- **Updated regulatory systems** as the technologies and systems in which they are used continue to evolve,
- Promote **reliance** between regulatory authorities and other stakeholders
- Facilitating **international cooperation**
- Facilitate the **adoption of effective and efficient approaches** to ensure the quality, safety and performance of medical products in the global regulatory community.
- **Serve and protect public health** and the interests of parties.

This document is complemented by the following guides:

- Good Governance Practices
  - **Good Reliance Practices**
  - Good Review Practices
  - Quality Management System for National Regulatory Authorities
- 





## Good Regulatory Practices

### Facilitators

- Political and government support
- Good organization, governance and leadership
- Effective communication, collaboration and coordination
- Robust and functional Quality Management System
- Sufficient and sustainable financial resources
- Competent human resources
- Ethics and pre-established organizational values
- Regulatory decision-making process based on science and data

### Principles

1. Legality
2. Consistency
3. Independence
4. Impartiality
5. Proportionality
6. Flexibility
7. Clarity
8. Efficiency
9. Transparency

Adapted from Fig. 2 Principles and enablers of good regulatory practices (GRP) and components of a regulatory system. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1033). Licence: CC BY-NC-SA 3.0 IGO.



# ANNEX 11. GOOD REGULATORY PRACTICES

## HIGH-LEVEL PRINCIPLES

These are **practices** that must be **adopted** by all institutions responsible or involved in the regulation of medical products.


The nine high-level principles of Good Regulatory Practices are connected to the **Global Benchmarking Tool**.



# GLOBAL BENCHMARKING TOOL (GBT)

The Global Assessment Tool is the means by which WHO objectively evaluates regulatory systems, as provided in WHA 67.20 on strengthening the regulatory system for medical products.

Link: <https://www.who.int/tools/global-benchmarking-tools>





# REGULATORY FUNCTIONS OF THE GBT

Latest version of  
GBT+ comprises 10  
regulatory functions

1. National Regulatory System
2. Registration and marketing authorization
3. Vigilance
4. Market surveillance and control
5. Licensing establishments
6. Regulatory inspection
7. Laboratory testing
8. Clinical Trials Oversight
9. NRA Lot Release
10. Authorization of blood products



# WORKING GROUP FOR THE INTEGRATION OF MEDICAL DEVICE INDICATORS, INCLUDING IN VITRO DIAGNOSTIC INDICATORS IN GBT+

## OBJECTIVES

- Integration of medical devices, including IVD, into WHO GBT+,
- Identify new functions, indicators and sub-indicators specific to medical devices, including IVD, considering their particularities.


## EXPECTED RESULTS

- GBT + Medical Devices, with evaluation criteria for medical device regulatory systems including IVDs.
- Agreed next steps, including piloting the GBT + medical devices.



# WORKING GROUP FOR THE INTEGRATION OF MD, INCLUDING IVD INDICATORS IN THE GBT+

- WHO
  - HQ
  - EURO
  - PAHO
- Singapore - HSA
- Kingdom of Saudi Arabia - FDA Saudi
- France - HAS
- Region of the Americas:
  - Argentina - ANMAT
  - Brazil - ANVISA
  - Canada - Health Canada
  - Cuba - CECMED
  - Colombia - INVIMA
  - USA - FDA
  - Mexico - COFEPRIS








# DOCUMENT REGULATORY RELIANCE PRINCIPLES: CONCEPT NOTE AND RECOMMENDATIONS

- The purpose of the document is to present examples and key principles of reliance.
- The principles of this document were used as the basis for the WHO Good Practices in Reliance document.
- **Link:** <https://iris.paho.org/handle/10665.2/51550>





# ANNEX 10. GOOD PRACTICES OF RELIANCE IN THE REGULATION OF MEDICAL PRODUCTS

## REGULATORY CHALLENGES

- Globalization of markets
- Sophisticated health technologies
- Rapid evolution of regulatory science
- Increased complexity of supply chains

## STRATEGIES TO ADDRESS CHALLENGES

- ✓ Improve international collaboration to ensure the safety, quality and performance of locally used medical products.
- ✓ Make the most of the resources and technical knowledge available, avoid duplication, and concentrate regulatory efforts and resources where they are most needed.
- ✓ Formulation and implementation of strategies consistent with GRP to strengthen regulatory systems, including the search for cooperation and regulatory convergence, as well as reliance.



# ANNEX 10. GOOD RELIANCE PRACTICES IN THE REGULATION OF MEDICAL PRODUCTS

## PURPOSE

- Promote an **efficient approach to regulation**.
- Improve **access to safe, effective and quality medical products**.
- Present the **general principles** of regulatory review.
- Provide **high-level guidance, definitions, key concepts and considerations** to guide reliance mechanisms and activities.

## SCOPE

- Reliance activities in the regulation of **medical products**.
  - Drugs
  - Vaccines
  - blood and blood products, and
  - **Medical devices**, including in vitro diagnostic devices.




Addresses **every regulatory function** defined in the GBT throughout the product **lifecycle**

- It is intended for **all NRAs**, regardless of their level of maturity or resources, and policymakers, governments, industry and other stakeholders.



# ANNEX 10. GOOD RELIANCE PRACTICES IN THE REGULATION OF MEDICAL PRODUCTS



Taken from Fig. 1 Key concepts of reliance. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1033). License: CC BY-NC-SA 3.0 IGO.

# ANNEX 10. GOOD RELIANCE PRACTICES IN THE REGULATION OF MEDICAL PRODUCTS

## PRINCIPLES

### UNIVERSALITY

Applicable to all NRAs, regardless of maturity level or resources

### SOVEREIGNTY OF DECISION-MAKING

NRAs maintain their independence, sovereignty and responsibility in decision-making

### TRANSPARENCY

NRAs should be transparent about the standards, processes and approaches they adopt for the implementation of reliance

### RESPECT OF NATIONAL AND REGIONAL LEGAL BASES

Consistent with national or regional policy and regulatory frameworks

### CONSISTENCY


For specific and well-defined product categories and processes

### COMPETENCE

Develop and maintain appropriate scientific skills and knowledge

# WHO GLOBAL MODEL REGULATORY FRAMEWORK FOR MEDICAL DEVICES, INCLUDING IN VITRO DIAGNOSTIC MEDICAL DEVICES

- The Model recommends a **stepwise approach**, according to the **resources available** in each country, to regulate the quality, safety and performance of medical devices, and provides guidance for developing **progressively a regulatory system**.
- The approach starts with **basic controls** and then moves to **expanded controls**.
- It states that the **regulatory controls** that must be applied to each device are based on a **risk-based classification system**.
- It recommends reliance and recognition.
- **LINK:** <https://apps.who.int/iris/handle/10665/255177>



2017

## DOCUMENT UPDATE

The Working Group started activities in 2021 and continues with the review process





# WHO GLOBAL MODEL REGULATORY FRAMEWORK FOR MEDICAL DEVICES

EXPANDED LEVEL CONTROLS AND ENFORCEMENT		
Premarket	Placing on the market	Postmarket
<ul style="list-style-type: none"> <li>• Create oversight of clinical investigations</li> <li>• Appoint and have oversight of conformity assessment bodies</li> <li>• Recognize standards</li> <li>• Adopt a medical device nomenclature system</li> <li>• Control advertising and promotion</li> </ul>	<ul style="list-style-type: none"> <li>• Perform in-country quality management systems audits</li> <li>• Perform review of submissions for compliance with Essential Principles</li> </ul>	<ul style="list-style-type: none"> <li>• Establish within the regulatory authority a postmarket surveillance and vigilance reporting system</li> <li>• Require mandatory reporting by manufacturers of adverse events</li> <li>• Inspection of registered establishments</li> <li>• Provide for testing laboratories</li> </ul>

BASIC LEVEL CONTROLS AND ENFORCEMENT		
Premarket	Placing on the market	Postmarket
<ul style="list-style-type: none"> <li>• Publish law, including definition, and regulations, with transition period</li> <li>• Establish medical devices classification for regulatory purposes</li> <li>• Establish Essential Principles of safety and performance</li> <li>• Establish basis for reliance and recognition</li> <li>• Establish requirements for declaration of conformity</li> <li>• Establish requirements for manufacturers for a QMS</li> <li>• Establish requirements for labels and labelling</li> <li>• Prohibit deceptive, misleading and false advertising</li> <li>• Establish provisions for exceptional premarket situations</li> </ul>	<ul style="list-style-type: none"> <li>• Registration of establishments</li> <li>• Listing of medical devices</li> <li>• Import controls</li> </ul>	<ul style="list-style-type: none"> <li>• Establish a system for vigilance reporting</li> <li>• Require mandatory notification by the manufacturer of field safety corrective actions</li> <li>• Establish a procedure to withdraw unsafe medical devices from the market</li> <li>• Establish procedure to issue safety alerts to users</li> <li>• Undertake market surveillance</li> </ul>



# OPS 120

ANIVERSARIO

Thank you for  
your attention!



**PAHO**



Pan American  
Health  
Organization



World Health  
Organization  
REGIONAL OFFICE FOR THE  
Americas